OrthoPediatrics Earnings Call Transcripts
Fiscal Year 2026
-
Focused on pediatric orthopedics, the business is experiencing strong growth, driven by a robust new product pipeline, international expansion, and disciplined financial management. Recent regulatory approvals and acquisitions support margin and cash flow improvements, with a clear path to free cash flow breakeven by 2026.
-
Q1 2026 saw 13% revenue growth, strong international and OPSB expansion, and improved profitability. Guidance was raised for 2026, with new product launches and regulatory wins expected to drive further growth and margin expansion.
-
Clinic expansion is ahead of schedule, with strong revenue and cash flow improvements. New enabling technologies and a robust product pipeline are driving growth, while international and digital initiatives are expanding. Financial outlook remains stable with improved margins and cash flow.
-
A robust new product cycle is underway, with multiple launches in surgical, bracing, and enabling tech segments expected to drive growth through 2028. Financial performance is improving, with positive free cash flow targeted for 2026 and ongoing expansion of the specialty bracing business. Reduced competition due to regulatory changes is creating additional market opportunities.
-
Strong Q4 results included the first quarter of positive free cash flow and robust EBITDA growth. 2026 guidance targets 11%-13% revenue growth, $25M adjusted EBITDA, and break-even cash flow, driven by new product launches, international expansion, and a unique pediatric focus that limits competition.
Fiscal Year 2025
-
Q4 2025 saw 17% revenue growth, record free cash flow, and strong gross margins, driven by innovation and international expansion. 2026 guidance projects 11%-13% revenue growth, $25M Adjusted EBITDA, and breakeven FCF, with a robust product pipeline and new market entries.
-
Guidance was reset to focus on predictable, high-margin growth, excluding volatile 7D and Latin America set sales. New product launches and international expansion are expected to drive growth from 2026, with a strong scoliosis and OPSB portfolio and significant EBITDA improvement anticipated.
-
A pediatric orthopedics-focused company is expanding its global reach and product portfolio through innovation, acquisitions, and education, targeting $233.5M-$234.5M revenue and $15M-$17M EBITDA in 2025. Specialty bracing and enabling technology drive growth, with free cash flow break-even expected in 2026.
-
Trauma Deformity and OPSB divisions are driving strong growth, with new product launches and clinic expansion ahead of plan. Financial guidance has been rebased to a 12% baseline growth, focusing on profitability and cash flow, while a robust innovation pipeline and favorable market dynamics support long-term expansion.
-
Q3 2025 saw 12% revenue growth, strong core segment performance, and a 56% rise in adjusted EBITDA, despite headwinds from 7D and LATSAM. Guidance for 2025 remains positive, with profitability and free cash flow improvements expected, and new product launches and clinic expansions driving future growth.
-
Revenue guidance for 2025 was lowered due to unpredictable 7D capital sales and LATAM headwinds, but core business segments continue to show strong, high-margin growth. Long-term annual growth is now set at 12%+, with free cash flow break-even targeted for 2026.
-
Exclusive focus on pediatric orthopedics has driven robust growth, with record Q2 revenue and expanding global reach. Specialty bracing and innovative products like VertiGlide and ELLY are key growth drivers, while financials project continued margin improvement and cash flow break-even in 2024.
-
Q2 2025 saw record revenue growth of 16% year-over-year, led by strong performance in scoliosis, trauma, and OPSB, with robust U.S. and international demand. Guidance was raised, and the company expects positive free cash flow in Q4 2025 and break-even in 2026.
-
Q1 2025 saw 17% revenue growth, improved profitability, and strong performance across trauma, deformity, scoliosis, and OPSB segments. Guidance was raised, with expectations for 15–18% annual revenue growth and positive free cash flow by Q4 2025.
-
Pediatric hospitals have adapted to infection spikes, reducing business impact. Specialty bracing and OPSB expansion drive growth, with new products like DF2, 3P plating, and next-gen scoliosis systems fueling innovation. Gross margins are stable at 72–73% with minimal tariff risk.
Fiscal Year 2024
-
Q4 revenue grew 40% year-over-year to $52.7M, with strong U.S. and segment growth, and adjusted EBITDA more than doubled. 2025 guidance calls for 15–18% revenue growth, continued margin strength, and first positive free cash flow in Q4. OPSB and new product launches are key growth drivers.
-
Growth is driven by PNP Femur and Tibia systems, with new plating and spine products set to launch in 2025–2026. Specialty bracing expansion and the Boston O&P acquisition are fueling revenue growth, while profitability is improving through operational leverage.
-
Stock volatility was linked to external fund liquidation, while core business performance remains strong with significant share gains in scoliosis and robust adoption of new technologies like 7D navigation. High teens sales growth and expanding specialty bracing clinics are expected to drive future results.
-
Q3 2024 saw record revenue of $54.6M (+37% YoY), driven by strong growth in all segments and robust product launches. Full-year guidance was raised to $202–$204M, with continued margin strength and a focus on cash flow breakeven by 2026.
-
Revised summary: The company targets high-teens revenue growth and cash flow positivity by 2026, driven by specialty bracing expansion, new trauma, deformity, and scoliosis products, and enabling technologies. Strategy includes deeper hospital penetration, clinic expansion, and leveraging digital health while maintaining strong margins and efficiency.
-
Q2 2024 revenue hit a record $52.8M, up 33% year-over-year, driven by strong T&D, Scoliosis, and OPSB growth, with gross margin rising to 77%. Guidance for 2024 is reaffirmed at $200–$203M revenue and $8–$9M adjusted EBITDA, with cash flow breakeven targeted by 2026.
-
The business is evolving into a comprehensive pediatric orthopedics provider, with specialty bracing and clinic expansion driving growth. New product launches in scoliosis and strong performance in bracing and Pega segments support a 20% growth aspiration, while investments remain manageable.